Streetbeat News

Products Services

TTE

TotalEnergies has signed a 15-year renewable Power Purchase Agreement (PPA) with Saint-Gobain to supply solar power to Saint-Gobain's 125 industrial sites in North America. The power will be supplied from TotalEnergies' Danish Fields Solar farm in Texas, which is expected to come online in 2024. This is TotalEnergies' second long-term solar power supply agreement and is part of its commitment to offering renewable energy solutions to businesses worldwide.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 10:59 am

ANIP

ANI Pharmaceuticals has announced the FDA approval and commercial availability of a new 1-mL vial size of Purified Cortrophin Gel, which is used for the adjunctive treatment of certain patients with acute gouty arthritis flares. This is in addition to the 5-mL vial size that was launched in January 2022.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 10:52 am

NRXP

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has received FDA clearance to proceed with human trials for its Investigational New Drug (IND) application for NRX-101, aimed at treating Chronic Pain. The IND application is based on pioneering research on the use of D-cycloserine, a key ingredient of NRX-101, and a recently licensed US Patent for the use of D-cycloserine in pain treatment.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 10:49 am

LLY

The FDA has issued a Complete Response Letter for Eli Lilly's Lebrikizumab due to inspection findings at a third-party manufacturer. This could potentially delay the drug's approval process.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 10:46 am

TRX

TRX Gold has announced the arrival of a new 1,000-ton-per-day capacity ball mill at the Buckreef Gold Project. The company expects commercial production delivery to begin in the second half of fiscal year 2024.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 10:43 am

AAPL

META

Apple Inc. CEO Tim Cook has praised the company's first-generation mixed-reality headset, Vision Pro, and its potential for spatial computing. Cook revealed that the Vision Pro has become a part of his daily routine, allowing him to understand its potential as a game-changing product better. The Vision Pro headset is expected to launch in early 2024. In contrast, Apple’s rival in the AR/VR market, Meta Platforms Inc., has launched its Quest 3 headset at a starting price of only $499.

Portfolio Pulse from Ananya Gairola

October 02, 2023 | 10:39 am

CLRB

Cellectar Biosciences has secured four patents across Europe, Australia, and Canada for its proprietary phospholipid drug conjugate delivery platform and lead drug in development.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 10:36 am

CI

Cigna Healthcare has expanded its 2024 Medicare Advantage Plans, offering a $0 premium plan in every service market. All plans feature dental, vision, fitness, meals, and enhanced hearing benefits. The expansion reaches an additional 2.3 million potential customers, including both Medicare and dual eligible beneficiaries. The plans cater to every lifestyle, including Medicare Advantage plans, Medicare Supplement plans, and standalone Prescription Drug Plans.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 10:04 am

AAPL

Apple Inc.'s iPhone 15 models are experiencing delivery delays due to supply chain issues and high demand. The non-Pro models have delivery timelines of 12 to 15 days, while the Pro models have longer delivery timelines, with the Pro Max extending to as long as 40 days. However, these delays are easing, with the Pro Max delivery estimates improving from a peak of 54 days to an average of 40 days.

Portfolio Pulse from Rounak Jain

October 02, 2023 | 9:44 am

NVS

Novartis has announced positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study. The study demonstrated the superiority of Iptacopan, an investigational factor B inhibitor, versus placebo in proteinuria reduction. The safety profile of Iptacopan was consistent with previously reported data. The study continues to evaluate Iptacopan’s ability to slow IgAN progression.

Portfolio Pulse from Charles Gross

October 02, 2023 | 8:42 am